| The total follow-up period | The first six months | ||||||
---|---|---|---|---|---|---|---|---|
VTE (−) | VTE (+) | Total |  | VTE (−) | VTE (+) | Total |  | |
n = 25,899 (98.6%) | n = 357 (1.4%) | n = 26,256 (100%) | P value | n = 26,114 (99.5%) | n = 142 (0.5%) | n = 26,256 (100%) | P value | |
Mean age (years), mean ± SE | 54.17 ± 0.1 | 59.25 ± 0.6 | 54.24 ± 0.1 | <.001 a | 54.21 ± 0.1 | 58.35 ± 0.9 | 54.24 ± 0.1 | <.001 a |
SES, n (%) | Â | Â | Â | 0.101 | Â | Â | Â | 0.61 |
 Mid- or high- SES | 24,767 (95.6) | 335 (93.8) | 25,102 (95.6) |  | 24,965 (95.6) | 137 (96.5) | 25,102 (95.6) |  |
 Low SES | 1132 (4.4) | 22 (6.2) | 1154 (4.4) |  | 1149 (4.4) | 5 (3.5) | 1154 (4.4) |  |
CCI, n (%) | Â | Â | Â | <.001 | Â | Â | Â | 0.695 |
 0 | 14,299 (55.2) | 159 (44.5) | 14,458 (55.1) |  | 14,387 (55.1) | 71 (50) | 14,458 (55.1) |  |
 1 | 3464 (13.4) | 48 (13.4) | 3512 (13.4) |  | 3491 (13.4) | 21 (14.8) | 3512 (13.4) |  |
 2 | 4688 (18.1) | 76 (21.3) | 4764 (18.1) |  | 4738 (18.1) | 26 (18.3) | 4764 (18.1) |  |
 3 | 1366 (5.3) | 24 (6.7) | 1390 (5.3) |  | 1381 (5.3) | 9 (6.3) | 1390 (5.3) |  |
 Over 4 | 2082 (8) | 50 (14) | 2132 (8.1) |  | 2117 (8.1) | 15 (10.6) | 2132 (8.1) |  |
Year of endometrial cancer diagnosis, n (%) | Â | Â | Â | 0.101 | Â | Â | Â | 0.016 |
 2009 | 1991 (7.7) | 20 (5.6) | 2011 (7.7) |  | 2007 (7.7) | 4 (2.8) | 2011 (7.7) |  |
 2010 | 2099 (8.1) | 25 (7) | 2124 (8.1) |  | 2116 (8.1) | 8 (5.6) | 2124 (8.1) |  |
 2011 | 2238 (8.6) | 45 (12.6) | 2283 (8.7) |  | 2268 (8.7) | 15 (10.6) | 2283 (8.7) |  |
 2012 | 2319 (9) | 32 (9) | 2351 (9) |  | 2342 (9) | 9 (6.3) | 2351 (9) |  |
 2013 | 2508 (9.7) | 37 (10.4) | 2545 (9.7) |  | 2537 (9.7) | 8 (5.6) | 2545 (9.7) |  |
 2014 | 2553 (9.9) | 38 (10.6) | 2591 (9.9) |  | 2583 (9.9) | 8 (5.6) | 2591 (9.9) |  |
 2015 | 2686 (10.4) | 42 (11.8) | 2728 (10.4) |  | 2707 (10.4) | 21 (14.8) | 2728 (10.4) |  |
 2016 | 3081 (11.9) | 47 (13.2) | 3128 (11.9) |  | 3106 (11.9) | 22 (30) | 3128 (11.9) |  |
 2017 | 3326 (12.8) | 41 (11.5) | 3367 (12.8) |  | 3342 (12.8) | 25 (17.6) | 3367 (12.8) |  |
 2018 | 3098 (12) | 30 (8.4) | 3128 (11.9) |  | 3106 (11.9) | 22 (15.5) | 3128 (11.9) |  |
Primary treatments b, n (%) |  |  |  | 0.1 |  |  |  | < 0.001 |
 No treatement c | 5268 (20.3) | 70 (19.6) | 5338 (20.3) |  | 5307 (20.3) | 31 (20) | 5338 (20.3) |  |
 Surgery d | 17,386 (67.1) | 231 (64.7) | 17,617 (67.1) |  | 17,509 (67.1) | 108 (69.7) | 17,617 (67.1) |  |
 Radiotherapy ± chemotherapy | 544 (2.1) | 6 (1.7) | 550 (2.1) |  | 546 (2.1) | 4 (2.6) | 550 (2.1) |  |
 Chemotherapy | 723 (2.8) | 18 (5) | 741 (2.8) |  | 729 (2.8) | 12 (7.7) | 741 (2.8) |  |
Hormone therapy | 1978 (7.6) | 32 (9) | 2010 (7.7) | Â | 2010 (7.7) | 0 (0) | 2010 (7.7) | Â |
Surgery, n (%) | ||||||||
 Total hysterectomy | 9874 (56.8) | 113 (48.9) | 9987 (56.7) | 0.016 | 9932 (56.7) | 55 (50.9) | 9987 (56.7) | 0.225 |
 Radical hysterectomy | 7512 (43.2) | 118 (51.1) | 7630 (43.3) | 0.016 | 7577 (43.3) | 53 (49.1) | 7630 (43.3) | 0.225 |
Radiotherapy, n (%) | ||||||||
 CCRT | 16 (2.9) | 1 (16.7) | 17 (0) | 0.172 e | 17 (3.1) | 0 (0) | 17 (0) | 1 e |
 EBRT | 306 (56.3) | 5 (83.3) | 311 (86.9) | 0.24 e | 308 (56.4) | 3 (75) | 311 (86.9) | 0.637 e |
 Brachytherapy | 313 (57.5) | 2 (33.3) | 315 (37.4) | 0.41 e | 314 (57.5) | 1 (25) | 315 (37.4) | 0.318 e |
Chemotherapy, n (%) | ||||||||
 Platinum (cisplatin, carboplatin) | 203 (48.2) | 11 (61.1) | 214 (48.7) | 0.442 | 506 (69.6) | 8 (66.7) | 514 (69.6) | 0.764 e |
 Other agents | 218 (51.8) | 7 (38.9) | 225 (51.3) | 0.426 | 221 (30.4) | 4 (33.3) | 225 (30.4) | 0.761 e |
 Bevacizumab | 16 (3.8) | 0 (0) | 16 (3.6) | 1 e | 16 (2.2) | 0 (0) | 16 (2.3) | 1 e |
Hormone therapy | ||||||||
 Progestins | 1823 (74.6) | 29 (72.5) | 1852 (74.5) | 0.736 e | 1852 (74.5) | 0 (0) | 1852 (74.5) | 1 e |
 Tamoxifen | 49 (2) | 2 (5) | 51 (2.1) | 0.194 e | 51 (2.1) | 0 (0) | 51 (2.1) | 1 e |
 Progestins and Tamoxifen | 33 (1.3) | 2 (5) | 35 (1.4) | 0.106 e | 35 (1.4) | 0 (0) | 35 (1.4) | 1 e |
 Aromatase inhibitors | 69 (2.8) | 4 (10) | 73 (2.9) | 0.027 e | 73 (2.9) | 0 (0) | 73 (2.9) | 1 e |
 Gonadotropin-releasing hormone agonists | 21 (0.9) | 1 (2.5) | 22 (0.9) | 0.299 e | 22 (0.9) | 0 (0) | 22 (0.9) | 1 e |
 Levonorgestrel-releasing intrauterine system | 450 (18.4) | 2 (5) | 452 (18.2) | 0.027 | 452 (18.2) | 0 (0) | 452 (18.2) | 1 e |
Time between primary treatments and VTE diagnosis (days), mean ± SE |  | 526.8 ± 46.4 |  |  |  | 79.9 ± 7.5 |  |  |